PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 12, 20260 citationsOpen Access

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis.

View Full Paper
HQHuijie QiYHYuxin HuangWZWen Zhang

Key Points

  • To assess the cost-effectiveness of immune checkpoint inhibitor-based therapies for advanced hepatocellular carcinoma (HCC).
  • Conducted a network meta-analysis of available therapies for HCC.
  • Compared cost-effectiveness of camrelizumab plus rivoceranib with other options in different healthcare settings.
  • Analyzed existing pricing and outcomes in the United States and China.
  • Camrelizumab plus rivoceranib is cost-effective for HCC treatment in China.
  • Current immune checkpoint inhibitor therapies are not cost-effective in the United States at current prices.
  • Findings can guide treatment choices and health policy decisions in various healthcare systems.

Abstract

Camrelizumab plus rivoceranib represents a cost-effective first-line therapy for advanced or unresectable HCC in China. In the United States, current ICI-based therapies are not cost-effective at existing prices. These findings may inform treatment selection and health policy decision-making in different healthcare systems.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Qi et al. (2026) studied this question.

synapsesocial.com/papers/69b25b0996eeacc4fcec94c0https://doi.org/10.1177/17588359261417630
Ask AI
Helpful
Bookmark
Share
View Full Paper